When it comes to cancer research, few people have the resume of Dr. Clay Siegall. This guy is one of the most trusted and respected figures in the field today. He is highly accomplished with a B.S. in Zoology and a Ph.D in Genetics. He is also the holder of at least 15 patents. That right there is more than a lifetime of accomplishments, but this man has dedicated himself to fighting cancer. Siegall just so happens to be the president and founder of Seattle Genetics. This biotech company is one of the very best cancer fighting institutions in the world. It has well-over 1,000 employees, and it’s one of the biggest employers in the Pacific Northwest.
Siegall has implemented his three main principles into fighting this disease. Drug development, rigorous research and scientific innovation. Systemic chemotherapies are a thing of the past as this is a new day. Antibody-based therapies are the weapon of choice, and these medications have a much better track record than its predecessors. These therapies are actually broken down into antibody drug conjugates, and they efficiently attack cancer cells within the human body. Unlike past cancer therapies, antibody drug conjugates won’t cause the patient to feel sick, which is one of the nasty side effects with cancer medications. All of the good cells are spared while these advanced medications are at work.
Siegall and ADECTRIS, the company’s flagship drug, has helped to bring in $350 million in capital. This comes in part by securing multiple strategic licenses with prominent medical companies. These companies just so happen to be Bayer, Pfizer, Genentech and GlaxoSmithKline. The once small startup company has turned into a global powerhouse, but Seattle Genetics didn’t really start making large amounts of money until after it received its IPO. The future of the fight against cancer is looking mighty bright and Dr. Clay Siegall stands at the forefront of it all.